P2RY12 and coronary artery disorder: P2Y12 is currently a clinically determined antiplatelet drug target, and P2Y12 antagonists, such as clopidogrel, prasugrel, or ticagrelor, are clinically used in patients with coronary heart disease to inhibit platelet aggregation [118].